Brief: ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy And Combination Therapy Clinical Development
27/06/2022 21:41
June 27 (Reuters) - ESSA Pharma Inc EPIX.O :
* ESSA PHARMA PRESENTS CLINICAL UPDATE ON EPI-7386
MONOTHERAPY AND
COMBINATION THERAPY CLINICAL DEVELOPMENT
* ESSA PHARMA INC - EPI-7386 WAS SAFE AND WELL-TOLERATED AT
ALL
DOSE LEVELS
* ESSA PHARMA INC - EPI-7386 SCHEDULES TESTED WITH PLASMA
TARGET
CONCENTRATIONS ACHIEVED AND CLINICALLY IMPORTANT EFFICACY
SIGNALS
* ESSA PHARMA INC - EXPECTS TO INITIATE PHASE 1B MONOTHERAPY
EXPANSION STUDY IN Q3 2022
Source text for Eikon: ID:nCNW5sGZra
Further company coverage: EPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ESSA Pharma
See all newsBrief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: ESSA Pharma Provides Update On Its Application To The Supreme Court Of British Columbia For Amended Interim Order
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics